BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 18625954)

  • 21. [Intravitreal rituximab for the treatment of intraocular relapse of non-Hodgkin's lymphoma].
    Fernández Cañabate E; Fernández-Cañabate S
    Farm Hosp; 2018 Jan; 42(1):20-21. PubMed ID: 29306309
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preclinical study of Ublituximab, a Glycoengineered anti-human CD20 antibody, in murine models of primary cerebral and intraocular B-cell lymphomas.
    Ben Abdelwahed R; Donnou S; Ouakrim H; Crozet L; Cosette J; Jacquet A; Tourais I; Fournès B; Gillard Bocquet M; Miloudi A; Touitou V; Daussy C; Naud MC; Fridman WH; Sautès-Fridman C; Urbain R; Fisson S
    Invest Ophthalmol Vis Sci; 2013 May; 54(5):3657-65. PubMed ID: 23611989
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intraocular (vitreoretinal) lymphoma following primary testicular lymphoma.
    Grange LK; Jacobs-El N; Wiley HE; Kurup S; Chan CC; Sen HN
    Can J Ophthalmol; 2013 Aug; 48(4):e95-7. PubMed ID: 23931497
    [No Abstract]   [Full Text] [Related]  

  • 24. Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab.
    Tai WM; Chung J; Tang PL; Koo YX; Hou X; Tay KW; Quek R; Tao M; Lim ST
    Ann Hematol; 2011 Jul; 90(7):809-18. PubMed ID: 21229246
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rituximab: active treatment of central nervous system involvement by non-Hodgkin's lymphoma?
    Ruhstaller TW; Amsler U; Cerny T
    Ann Oncol; 2000 Mar; 11(3):374-5. PubMed ID: 10811510
    [No Abstract]   [Full Text] [Related]  

  • 26. Central nervous system vasculitis: all that glitters is not gold.
    Haroon M; Molloy E; Farrell M; Alraqi S
    J Rheumatol; 2012 Mar; 39(3):662-3. PubMed ID: 22383360
    [No Abstract]   [Full Text] [Related]  

  • 27. Diffuse large B-cell lymphoma and mantle cell lymphoma of the ocular adnexal region, and lymphoma of the lacrimal gland: an investigation of clinical and histopathological features.
    Rasmussen PK
    Acta Ophthalmol; 2013 Jul; 91 Thesis 5():1-27. PubMed ID: 24041159
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma.
    Abramson JS; Hellmann M; Barnes JA; Hammerman P; Toomey C; Takvorian T; Muzikansky A; Hochberg EP
    Cancer; 2010 Sep; 116(18):4283-90. PubMed ID: 20564149
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regression of refractory intraocular large B-cell lymphoma with lenalidomide monotherapy.
    Rubenstein JL; Treseler PA; Stewart PJ
    J Clin Oncol; 2011 Jul; 29(20):e595-7. PubMed ID: 21519022
    [No Abstract]   [Full Text] [Related]  

  • 30. Retrospective analysis of primary gastric diffuse large B cell lymphoma in the rituximab era: a multicenter study of 95 patients in Japan.
    Tanaka T; Shimada K; Yamamoto K; Hirooka Y; Niwa Y; Sugiura I; Kitamura K; Kosugi H; Kinoshita T; Goto H; Nakamura S
    Ann Hematol; 2012 Mar; 91(3):383-90. PubMed ID: 21822617
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Isolated central nervous system relapses in primary mediastinal large B-cell lymphoma after CHOP-like chemotherapy with or without Rituximab.
    Papageorgiou SG; Diamantopoulos P; Levidou G; Angelopoulou MK; Economopoulou P; Efthimiou A; Constantinou N; Katsigiannis A; Korkolopoulou P; Pappa V; Economopoulou C; Georgiou G; Dimou M; Tsirigotis P; Kyrtsonis MC; Kotsianidis I; Kalpadakis C; Dimopoulos MA; Beris P; Meletis J; Pangalis GA; Dervenoulas J; Panayiotidis P; Vassilakopoulos TP
    Hematol Oncol; 2013 Mar; 31(1):10-7. PubMed ID: 22610484
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intravascular large B-cell lymphoma: remission after rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy.
    Horváth B; Demeter J; Eros N; Hársing J; Csomor J; Matolcsy A; Bottlik G; Gyori G; Marschalkó M; Kárpáti S
    J Am Acad Dermatol; 2009 Nov; 61(5):885-8. PubMed ID: 19632742
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rituximab for BCL-2-positive cancers.
    Boughton B
    Lancet Oncol; 2003 Feb; 4(2):69. PubMed ID: 12573343
    [No Abstract]   [Full Text] [Related]  

  • 34. Rituximab in diffuse large B-cell lymphoma.
    Coiffier B
    Clin Adv Hematol Oncol; 2004 Mar; 2(3):156-7. PubMed ID: 16166943
    [No Abstract]   [Full Text] [Related]  

  • 35. Intrathecal rituximab treatment for pediatric post-transplant lymphoproliferative disorder of the central nervous system.
    van de Glind G; de Graaf S; Klein C; Cornelissen M; Maecker B; Loeffen J
    Pediatr Blood Cancer; 2008 Apr; 50(4):886-8. PubMed ID: 17668865
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma.
    Rubenstein JL; Fridlyand J; Abrey L; Shen A; Karch J; Wang E; Issa S; Damon L; Prados M; McDermott M; O'Brien J; Haqq C; Shuman M
    J Clin Oncol; 2007 Apr; 25(11):1350-6. PubMed ID: 17312328
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Waxing and waning intravascular large cell lymphoma with widespread organ infiltration.
    Vos JM; Bordbar A; Vet RJ; Pals ST; Kater AP
    Leuk Lymphoma; 2011 Apr; 52(4):705-8. PubMed ID: 21190427
    [No Abstract]   [Full Text] [Related]  

  • 38. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
    Mappa S; Marturano E; Licata G; Frezzato M; Frungillo N; Ilariucci F; Stelitano C; Ferrari A; Sorarù M; Vianello F; Baldini L; Proserpio I; Foppoli M; Assanelli A; Reni M; Caligaris-Cappio F; Ferreri AJ
    Hematol Oncol; 2013 Sep; 31(3):143-50. PubMed ID: 23161567
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Diagnostic problems in case of primary central nervous system lymphoma].
    Dubik-Jezierzańska M; Pokryszko-Dragan A; Turek T; Budrewicz S; Pawlik B
    Wiad Lek; 2006; 59(7-8):552-6. PubMed ID: 17209358
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The therapeutic effect of rituximab on CD5-positive and CD5-negative diffuse large B-cell lymphoma.
    Hyo R; Tomita N; Takeuchi K; Aoshima T; Fujita A; Kuwabara H; Hashimoto C; Takemura S; Taguchi J; Sakai R; Fujita H; Fujisawa S; Ogawa K; Motomura S; Suzuki R; Ishigatsubo Y
    Hematol Oncol; 2010 Mar; 28(1):27-32. PubMed ID: 19358143
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.